Anixa Biosciences
ANIX
15 hedge funds and large institutions have $2.65M invested in Anixa Biosciences in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 5 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
0.34% less ownership
Funds ownership: 5.07% → 4.73% (-0.34%)
17% less funds holding
Funds holding: 18 → 15 (-3)
18% less capital invested
Capital invested by funds: $3.25M → $2.65M (-$594K)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$151K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$144K |
| 3 |
SBH
Segall Bryant & Hamill
Chicago,
Illinois
|
+$64.5K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$14.8K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$106K |
| 2 |
VF
Virtu Financial
New York
|
-$101K |
| 3 |
Bank of New York Mellon
New York
|
-$10.8K |
| 4 |
CAM
Concorde Asset Management
Ann Arbor,
Michigan
|
-$5.63K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4K |
ANIX Hedge Fund Activity: Q2 2018 in Review
15 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q2 2018, worth a combined $2.65M — down 18% from $3.25M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ANIX and 3 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 5 added.
The largest buyer was BlackRock, adding an estimated $151K. The largest seller was Goldman Sachs, exiting entirely with an estimated $106K sold.
- 15 institutional investors held Anixa Biosciences (ANIX) as of Q2 2018, down from 18 in Q1 2018.
- Funds reported $2.65M of Anixa Biosciences stock for Q2 2018, down 18% quarter-over-quarter.
- 3 funds opened new Anixa Biosciences positions in Q2 2018 and 5 closed out, a net change of -2 holders.
- The largest Anixa Biosciences buyer in Q2 2018 was BlackRock, an estimated $151K added.
- The largest Anixa Biosciences seller in Q2 2018 was Goldman Sachs, an estimated $106K sold.
Based on aggregated 13F filings for Q2 2018.